The Annual General Meeting approved a total dividend of CHF 2.20 per share for the 2024/25 financial year (CHF 2.00 per share in 2023/24), half from retained earnings and half from capital contribution reserves. This corresponds to a total distribution of CHF 30.0 million. In addition, the shareholders approved the company’s management report, financial statements, remuneration report and report on non-financial matters.

Furthermore, shareholders ratified the introduction of Art. 3a in the company’s Articles of Association setting the capital band at CHF 183.5 million (lower bound) to CHF 212.5 million (upper bound) until 01 July 2030.
 
Marie-Pierre Zerr was elected as a new Member of the Board of Directors, replacing Betül Susamis Unaran who was not standing for re-election. 

With the addition of Marie-Pierre Zerr, our Board of Directors gains a seasoned expert in manufacturing and operations excellence. She has gained over 20 years of leadership experience from roles at Mercedes-Benz, Daimler Trucks, and Stellantis. Her expertise is a perfect fit for Ypsomed as we continue to expand our global manufacturing footprint,

said Simon Michel, Ypsomed CEO, at the Annual General Meeting.

Gilbert Achermann, Paul Fonteyne, Dr. Martin Münchbach, and Simon Michel were confirmed as Members of the Board. Gilbert Achermann was further re-elected as President of the Board of Directors. The shareholders also re-elected Gilbert Achermann and Paul Fonteyne as members of the Nomination & Compensation Committee.

Together with the Board, I look forward to continuing to shape Ypsomed’s future. Our goal is clear: to lead the world in subcutaneous self-injection technology,

said Gilbert Achermann upon his re-election as Chairman of the Board.

The next Annual General Meeting of Ypsomed will take place on 1 July 2026.

Detailed reporting and further information available here:
Documents related to the Annual General Meeting 2025